Festival of Biologics USA, World Immunotherapy 2022

Sirpiglenastat (DRP-104), a broad acting glutamine antagonist, metabolically reprograms glutamine addicted cancer cells and significantly remodels the tumor microenvironment leading to anti-tumor immune responses
Download

Dracen to work closely with FDA to advance the clinical program for the treatment of NSCLC with specific mutations

Dracen Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the Company’s Continue reading →

Posters characterize MOA and consistent single agent activity in KEAP1 mutant tumors
Dracen Pharmaceuticals Inc., announced today that two posters profiling its lead glutamine antagonist, DRP-104, will be presented June 22-24 during the American Association for Cancer Research Virtual meeting. Continue reading →

Targeting Glutamine Metabolism Enhances Tumor Specific Immunity by Modulating Suppressive Myeloid Cells
Journal of Clinical Investigation (2020) 131859

Tumor Microenvironment, Metabolism, and Immunotherapy
New England Journal of Medicine (2020) 382:869-887

Glutamine Blockade Induces Divergent Metabolic Programs to Overcome Tumor Immune Continue reading →

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Dracen Pharmaceuticals Announces Oral Presentation at Festival of Biologics World Immunotherapy Congress 2022
March 18, 2022
PDF Version

Dracen Announces DRP-104 (sirpiglenastat) Presentation at ASCO 2021 Virtual Annual Meeting
June 3, 2021
PDF Version

Dracen Announces DRP-104 (sirpiglenastat) Presentations at Continue reading →

ASCO 2021

Trial in progress abstract: Phase 1 & phase 2a, first-in-human study (FIH) of DRP-104, a broad glutamine antagonist, in adult patients with advanced solid tumors
Melissa Johnson, Deborah Doroshow, Tanguy Y. Seiwert, Michael K. Gibson, Vamsidhar Velcheti, Aaron Continue reading →

November 8, 2019
Dracen Pharmaceuticals announces DRP-104 presentations at the 2019 Society of Immunotherapy of Cancer (SITC) Meeting

Dracen Announces AACR Presentation
April 12, 2018
PDF Version

Dracen Closes Financing to Advance Immunometabolism Pipeline
March 22, 2018
PDF Version

Dracen Continue reading →